Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2003-04-23
2010-02-16
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024300, C536S024330, C536S024500
Reexamination Certificate
active
07662794
ABSTRACT:
The present invention provides DNAzymes and ribozymes that specifically cleave PAI-1-encoding mRNA. The present invention also provides antisense oligonucleotides that specifically inhibit translation of PAI-1-encoding mRNA. The invention also provides various methods of inhibiting the expression of PAI-1, and methods of treating diseases by such. Finally the invention provides pharmaceutical compositions containing the instant DNAzymes, ribozymes, antisense oligonucleotides, or other inhibitors of PAI-1 expression as active ingredients.
REFERENCES:
patent: 5985558 (1999-11-01), Dean
patent: 2003/0199463 (2003-10-01), Itescu
patent: 2001-507688 (2001-06-01), None
patent: WO-98/28317 (1998-07-01), None
patent: WO 01/51085 (2001-07-01), None
patent: WO/01/58476 (2001-08-01), None
GenBank Accession Nos. X13338; X13323; M24067; X16383; X52906; AF069712; AF074325; X04744; X04429; X12701; M22313.1; J05206; and M33960.
Peracchi, A. Prospects for antiviral ribozymes and deoxyribozymes. Reviews in Medical Virology, 2004 vol. 14:47-64.
Nielsen, PE. Systemic delivery. The last hurdle? Gene Therapy, 2005 vol. 12:956-957.
Santiago et al. New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. Nature Medicine, 1999 vol. 5:1264-1269.
Liu et al. Suppression of platelet-type-12-lipoxygenase activity in human erythroleukemia cells by an RNA-cleaving DNAzyme. Biochemical and Biophysical Research Communications, 2001 vol. 284:1077-1082.
Xiang et al. Downregulated expression of plasminogen activator inhibitor-1 augments myocardial neovascularization and reduces cardiomyocyte apoptosis after acute myocardial infarction. Journal of the American College of Cardiology, 2005 vol. 46:536-541.
Xiang et al. Down-regulation of plasminogen activator inhibitor 1 expression promotes myocardial neovascularization by bone marrow progenitors. Journal of Exp. Med., 2004 vol. 200:1657-1666.
International Search Report issued Aug. 14, 2003 in connection with International Application No. PCT/US03/12767.
Santorio, S.W. et al., A general purpose RNA cleaving DNA enzyme. Proc. Natl. Acad. Sci. USA. 94, 4262 4266 (1997).
Bennett, M.R. et al., Antisense therapy for angioplasty restenosis: some critical considerations. Circulation 92, 1981 1993 (1995).
Steffanson, S, and Lawrence, D.A. Nature 383, 441 443 (1996).
Heymans, S. et al. “Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs . . .” Nat. Med. 5: 1135-1142.
Ginsburg, D. et al., cDNA Cloning of Human Plasminogen Activator-Inhibitor from Endothelial Cells, J. Clin. Ivest. 78(6):1673-1680 (1986).
Sane, D.C. et al., PCR-based production of a ribozyme to Plasminogen Activator-Inhibitor-1, Biotechniques 18(2):208-210 (1995).
Santorio, Stephen W. et al. A general purpose RNA-cleaving DNA enzyme, Proc. Natl. Acad. Sci. USA 94:4262-4266 (1997).
Rerolle et al., Plasminogen activator inhibitor type 1 is a potential taret in renal fibrogenesis, Kidney International, 58:1841-1850 (2000).
Branch, A., A good antisense molecule is hard to find, TIBS 23:45-50 (1998).
Usman et al., Hammerhead ribozyme engineering, Current Opinion in Structural Biology, 1:527-533 (1996).
European Supplementary Partial Search Report issued Feb. 5, 2007 in connection with E.P. 03724216.1.
Buczko, W. (1997), Pharmacology and Therapeutics 76(1-3): 161-175.
Cierniewski, C.S. (1995), European Journal of Biochemistry, 227 (1/2):494-499.
Office Action issued Sep. 26, 2003 in connection with U.S. Appl. No. 10/128,706.
Final Office Action issued Mar. 6, 2006 in connection with U.S. Appl. No. 10/128,706.
Official Action issued Sep. 26, 2007 in connection with EP 03724216.1.
Official Action issued Jun. 6, 2008 in connection with corresponding European Patent Application No. EP 03724216.1.
Official Action issued Jul. 30, 2008 in connection with corresponding Israeli Patent Application No. 164674.
Apr. 10, 2009 Decision of Rejection issued in the connection with the counterpart Chinese Patent Application No. 03814714.9.
Apr. 14, 2009 Official Action issued in connection with the counterpart Japanese Patent Application No. 2003-587981.
Feb. 6, 2009 Communication Pursuant to Article 94(3) EPC in connection with European Patent Application No. EP03724216.1.
Agrawal et al. (2000) “Antisense Therapeutics: Is It as Simple as Complementary Base Recognition?”Molec. Med. Today6:72-81.
Liu et al. (2001) “Suppression of Platelet-Type 12-Lipoxygenase Activity in Human Erythroleukemia Cells by an RNA-Cleaving DNAzyme”Biochem. and Biophys. Research Comms. 284:1077-1082.
Peracchi, A. (2004) “Prospects for Antiviral Ribozymes and Deoxyribozymes”Rev. Med. Virol. 14:47-64.
Santiago et al. (1999) “New DNA Enzyme Targeting Egr-1 mRNA Inhibits Vascular Smooth Muscle Proliferation and Regrowth After Injury”Nature Med. 5:1264-1269.
Sawa et al. (1994) “Inhinition of Type-1 Plasminogen Activator Inhibitor Production by Antisense Oligonucleotides in Human Vascular Endothelial and Smooth Muscle Cells”J. Bio. Chem. 269:14149-14152.
Cooper & Dunham LLP
Gibbs Terra Cotta
McGarry Sean
The Trustees of Columbia University in the City of New York
White John P.
LandOfFree
DNA enzyme to inhibit plasminogen activator inhibitor-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with DNA enzyme to inhibit plasminogen activator inhibitor-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA enzyme to inhibit plasminogen activator inhibitor-1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4215547